P-ISSN: 3025-6518
E-ISSN: 3025-0501

Almakki Health Informatics Journal

A PHARMACOGENOMIC STUDY TO PREDICT REVERSE REMODELING

Mohammad Afies
Universitas Brawijaya Malang
Email : mc16afiez@gmail.com

KEYWORDS

cardiac remodeling, autonomic nervous system, heart failure, pharmacogenomics, genetic polymorphisms

ABSTRACT

Cardiac remodeling refers to structural, functional, and molecular changes in the heart in response to stress or injury. These alterations, involving both cellular and interstitial changes, contribute to the progression of heart disease. Long-term activation of the autonomic nervous system (ANS) exacerbates these changes, leading to systemic vasoconstriction, sodium and water retention, and ventricular remodeling, which accelerates disease progression. Neurohormonal activation is essential in compensating for falling cardiac output in heart failure (HF), but it also plays a major role in the progression of the disease. This study explores the role of the renin-angiotensin-aldosterone system (RAA) and the sympathetic nervous system in cardiac remodeling, particularly in heart failure, and the influence of genetic factors on drug response. The research focuses on the ß2-Adrenergic Gln/Gln Receptor genotype, a key genetic variant relevant to pharmacogenomics in left ventricular hypertrophy (LVH) treatment. Using a comprehensive review of clinical and experimental data, this study highlights how genetic polymorphisms affect the pharmacokinetics and pharmacodynamics of drugs such as beta-blockers, ACE inhibitors, and ARBs. The findings indicate that while the ß2-Adrenergic Gln/Gln Receptor genotype significantly influences drug efficacy, the challenges in applying personalized treatments based on genetic data require significant time and cost investments. The study's implications emphasize the need for personalized therapies and enhanced pharmacogenomic research to improve treatment outcomes in heart failure management, particularly in drug response and disease progression.

INTRODUCTION

A pharmacogenomics study is related to the different genetic makeups of every individual and influences the risk of developing diseases as well as responses to drugs and environmental factors. Genetic polymorphisms influence a drug's effect by altering its pharmacokinetics, pharmacodynamics, or both (Figure 1). Variations at a single base (SNPs) or sets of closely related SNPs (haplotypes) in genes involved at any stage of pharmacokinetics and pharmacodynamics that could affect the overall drug response of an individual (Ahmed et al., 2016; De Denus et al., 2008; Johnson & Cavallari, 2013; Mann et al., 2011; Mocan et al., 2021).



Figure 1. The impact of genetic polymorphisms on individuals' drug response
(Adapted from Ahmed et al.,2016)[1] ADRs, adverse drug reactions

Cardiac remodeling refers to the expression of the genome that causes modifications in the heart's structure, function, and size as a response of cardiac strain or injury. These alterations can also be cellular, interstitial, and molecular. The remodeling process is widely acknowledged as a predictor of the clinical course of heart failure (HF), and it is influenced by mechanical, genetic, and neurohormonal variables associated with worse outcomes and decreased survival. Clinical and experimental evidence suggests the renin–angiotensin– aldosterone (RAA) system and sympathetic nervous system play an important role in the process of ventricular remodeling.

Overall, genetic polymorphisms can significantly impact the pharmacokinetics and pharmacodynamics of beta-blockers and ACE inhibitors/ARBs, potentially influencing individual responses to these medications and contributing to inter-individual variability in treatment outcomes for conditions such as heart failure or hypertension (Cardoso et al., 2015; Cohn et al., 2000; Mann et al., 2011).

Genetic variations can significantly influence the pharmacokinetics of drugs, which include absorption, distribution, metabolism, and excretion (ADME). In terms of absorption, polymorphisms in genes encoding drug transporters or enzymes involved in intestinal absorption can impact the rate and extent of drug uptake. For instance, variations in P-glycoprotein (P-gp) expression, which is responsible for the transport of lipophilic drugs such as digoxin, beta-blockers like carvedilol and talinolol, and cholesterol synthesis inhibitors like lovastatin and atorvastatin, can affect the absorption efficiency of these drugs. Regarding distribution, genetic factors can alter plasma protein binding or influence the tissue distribution of drugs, leading to changes in how drugs are distributed across various body tissues. Additionally, polymorphisms in drug-metabolizing enzymes, particularly cytochrome P450 (CYP) enzymes, can result in different drug metabolism rates. For example, genetic variations in CYP2D6 may affect the metabolism of beta-blockers and angiotensin receptor blockers (ARBs) like losartan and irbesartan, influencing their efficacy and side effects. Lastly, genetic variations in renal transporters or enzymes responsible for drug excretion can affect the elimination rate of drugs. Alterations in renal clearance mechanisms may have a significant impact on the elimination of ACE inhibitors or ARBs, influencing drug accumulation or therapeutic outcomes. These pharmacokinetic variations underscore the importance of considering genetic factors in drug prescribing, particularly for medications with narrow therapeutic windows or variable responses among individuals (Ahmed et al., 2016; Cascorbi & al., 2004; Fajar et al., 2019; Petersen et al., 2011).

Genetic polymorphisms also play a significant role in pharmacodynamics, influencing drug-receptor interactions, downstream signaling pathways, and the physiological responses to drugs. Variations in receptors targeted by drugs, such as beta-blockers acting on β-adrenergic receptors or ACE inhibitors/ARBs targeting angiotensin receptors, can affect the affinity or sensitivity of these receptors to drug binding. These genetic variations can alter the drug's effectiveness or its side effects. Additionally, polymorphisms in genes that affect ion channels can modulate drug responses by influencing ion channel activity. For example, calcium-channel blockers, which inhibit the influx of calcium into cardiac and other muscle cells, may experience altered effectiveness depending on genetic differences. These blockers reduce chronotropic activity in cardiac pacemaker cells, reduce inotropy in other myocardium, and induce vasodilation in vascular smooth muscle. Finally, genetic polymorphisms in drug transporters and phase-1 drug-metabolizing enzymes can impact the pharmacokinetics and pharmacodynamics of drugs, including their metabolites. Enzyme variations, such as those affecting the structure or expression of proteins, can lead to differences in drug responses, especially in critical cardiovascular medications. These genetic factors emphasize the importance of considering genetic variations when prescribing drugs, particularly for conditions requiring precise and individualized treatment (Ahmed et al., 2016; Cascorbi & al., 2004).

Previous research by Ahmed et al. (2016) emphasized how genetic polymorphisms influence drug responses by affecting pharmacokinetics and pharmacodynamics, particularly in drugs used for heart failure and hypertension. They demonstrated that polymorphisms in genes like CYP2D6 and P-glycoprotein affect drug metabolism and absorption, leading to variations in drug efficacy and side effects among individuals. Similarly, research by Subur & Syata (2024) examined the genetic impact on drug responses in cardiovascular diseases, specifically focusing on beta-blockers and ACE inhibitors. This study confirmed that genetic factors significantly

contribute to inter-individual variability in drug responses. The novelty of this research lies in its specific focus on the ß2-Adrenergic Gln/Gln Receptor genotype and its relevance in pharmacogenomics for left ventricular hypertrophy (LVH). This research bridges a gap by focusing on this particular genotype and its potential role in modifying drug responses in cardiac remodeling, providing a deeper understanding of personalized treatments for heart failure patients.

This study aims to explore how genetic variations affect the pharmacokinetics and pharmacodynamics of these drugs in individuals with heart failure or LVH. The benefit of this research lies in its potential to advance personalized medicine by understanding how genetic factors influence drug responses, ultimately improving the effectiveness and safety of treatments for heart failure. By incorporating pharmacogenomics into treatment plans, healthcare providers can offer more targeted therapies, enhancing patient outcomes and minimizing adverse drug reactions.

RESEARCH METHOD

This study employs a quantitative research approach to examine the impact of genetic polymorphisms, specifically the ß2-Adrenergic Gln/Gln Receptor genotype, on the pharmacokinetics and pharmacodynamics of drugs used in the treatment of heart failure (HF) and left ventricular hypertrophy (LVH). The research utilizes secondary data, including clinical studies, genetic data, and drug response information related to the effects of beta-blockers and ACE inhibitors/ARBs. The population of this study consists of individuals diagnosed with HF or LVH, while the sample includes individuals with identified genetic variations in the ß2-Adrenergic Gln/Gln Receptor genotype.

The data collection method involves gathering genetic and clinical response data from existing clinical trials and pharmacogenomics studies. Data on drug efficacy and side effects, as well as genetic testing results, will be extracted from published clinical reports and research databases. The study uses purposive sampling to select studies that provide data on the ß2-Adrenergic Gln/Gln Receptor genotype in relation to drug responses in HF and LVH patients. The research instrument includes data collection forms to record genetic and clinical data, which will then be analyzed using statistical software such as SPSS to assess the relationship between genetic variations and drug response.

The data analysis technique includes regression analysis and correlation tests to evaluate how genetic polymorphisms in the ß2-Adrenergic Gln/Gln Receptor affect the pharmacokinetics and pharmacodynamics of beta-blockers and ACE inhibitors/ARBs (Dorn & Liggett, 2007; Iaccarino & al., 2006). This analysis will provide insights into the effectiveness of these drugs in individuals with different genetic profiles, helping to inform personalized treatment approaches for heart failure and LVH. The study's findings will contribute to the development of more targeted therapies, improving patient outcomes and reducing adverse drug reactions.

RESULTS AND DISCUSSION

Overview of Pharmacogenomics in Heart Disease and Literature Review

The drugs of HF, particularly beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARB), promote reverse remodeling. Beta-blockers work by suppressing the adrenergic pathway and interrupting chronic stimulation of the adrenergic receptor (AR) by circulating catecholamines like norepinephrine (NE) and epinephrine, which promote cardiac dysfunction. Renin-Angiotensin System Inhibitors, which include ACE- inhibitors, work by preventing the conversion of angiotensin I to angiotensin II, which is mediated by ACE. Angiotensin Receptor Blockers act by blocking the AT_1 receptors with concomitant stimulation of AT2, thus preventing the pathophysiological effects mediated by the binding of angiotensin II to

the AT_1 receptor. Both of the neurohormonal inhibitors above may reduce vasoconstriction, salt retention, and hypertrophy (Oni-Orisan & Lanfear, 2014).

Due to evidence of survival benefit, beta-beta blockers have been a mainstay of heart failure pharmacotherapy for almost 20 years, but there is great variation in response to beta blocker therapy, including certain subsets of the heart failure population that do not receive the same mortality and morbidity benefit. The difference in response to beta-blockers is influenced by inter-individual genetic variations (Table 1). Genetic polymorphisms can affect the pharmacokinetics of beta-blockers in the metabolic enzymes (for example, cytochrome P450 [CYP]2D6), whereas the pharmacodynamics of beta-blockers in the receptor genes and in other molecules influence the signaling pathway (Femminella et al., 2014; Oni-Orisan & Lanfear, 2014).

Polymorphisms cause changes in the amino acid sequence, and alterations in the regulationof signal transduction contribute to variability in responses to drugs. These are common polymorphisms in adrenergic signaling genes. Many studies have looked at associations of genetic polymorphisms of beta-AR genes with cardiac improvement or deterioration and beta- blockers. Some single nucleotide polymorphisms (SNPs) in the beta1-AR like Ser49Gly, Arg389Gly, beta2-AR Gly16Arg,Glu27Glu, α2C AR deletion, 322 and G-protein receptor kinase5 Gln41Leu may contribute to this variability in response to beta-blockers (Femminella et al., 2014; Oni-Orisan & Lanfear, 2014).

The RAAS is an important regulator of cardiovascular function and blood pressure and playsa key role during the development and worsening of heart failure. The renin-angiotensin-aldosterone and sympathetic nervous systems (RAAS and SNS) are critical in regulatory pathways of cardiac remodeling and activation of both systems stimulate protein synthesis in fibroblast and cardiomyocytes, leading to fibrosis and hypertrophy (Boulet & Mehra, 2021). Angiotensin convertingenzyme (ACE), Angiotensinogen(AGT) and Angiotensin II receptor (AGTR) act synergisticallyon the phenotype of blood pressure, cardiac remodeling serve to aggravate the hemodynamic status of patients with heart failure, accentuate symptoms, accelerate the progression of cardiacand vascular disease, and increase morbidity and mortality (Ahmed et al., 2016; Mann & McNamara, 2008).

Table 1. Common Polymorphisms in adrenergic signaling genes

Gene	Polymorphisme	Functional consequence	Therapeutic implication	Ref
ADRB1	49 Ser□ Gly	Gly49 had increased sensitivityto metoprolol as wellas enhanced catecholamine-induced β1-AR desensitization	Ser49 homozygotes had worsened prognosis (death orcardiac transplantation) compared to Gly49 carriers , considered a protective response to heart failure progression	Oni-Orisan and Lanfear, *Cardiol Rev*. 2014 ; 22(5): 193–198
	389 Ar□ Gly	Arg389 is associated with enhanced adrenergic responseto agonist stimulation of β1-ARin vitro and in vivo	Arg389Arg genotype better tolerated during the initiation ofbeta-blockers and had greatest improvement in LVEF with beta-blockers, and improved mortality with bucindolol.	Mann and McNamara, JACC Vol. 52, No. 8, 2008
ADRB2	16 Gly□ Arg	Increased downregulation	No reported interactions withbeta-blockers	Mann and McNamara, JACC Vol. 52, No. 8, 2008
			The Glu27 variant of β2AR enhances hypertension-	

Gene	Polymorphisme	Functional consequence	Therapeutic implication	Ref
	27 Gln□Glu	Decreased downregulation	induced LVH. In these patientsACE inhibitors (enalapril) are more efficient than -blockers (atenolol) in reducing cardiac size	*Iaccarino et al,* Clinical pharmacology & therapeutics 2006;80(6):633-45
ADRA2C	Del 322–325	Loss of function mutation leading to decreased NE uptake	Increased likelihood of developing HF in patients withthe beta1-AR Arg389 polymorphism; effect on drug responsiveness in HF not known	Mann and McNamara, JACC Vol. 52, No. 8, 2008
GRK5	41 Gln/Leu	Endogenous β-blocking effect	40% of African Americans whocarried one/two copies of the GRK5 Leu41 variant and were β-blocker naïve were protectedagainst death or cardiac transplantation	Dorn et al. Cardiac Adrenergic Pathway Pharmacogenomics , CTS, Volume 1,Issue 3

Genetic polymorphisms can effect the pharmacokinetics of RAAS in the metabolic enzymes; for example, losartan is essentially metabolized to its active form by cytochrome P450 [CYP]2C9 (Ahmed et al., 2016). The pharmacodynamics of RAAS in the receptor genes and in the other molecules involved in the signaling pathway. There are common polymorphisms in RAAS signaling genes, Single nucleotide polymorphisms (SNPs) in angiotensinogen, ACE, Angiotensin receptors genes of the RAA system may partially explain the variable effects received from ACE inhibitoror ARBs (Table 2.).

Table 2. Common Polymorphisms in RAAS signaling genes

Gen	Polymorphism	Functional consequence	Therapeutic implication	Ref
Angiotensinogen	Methionine (M)235□ Threonine (T)	elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy	Benefit (Decrease LVMi) from treatment (Irbesartan) after 12 weeks treatment as monotherapy, exhibit better responses to ACE inhibitor treatmentor AT1R blockade	Liljedahl et al, Journal of Hypertension 2004, 22:2321–2328, Pilbrow et al,, *Hypertension,* 2007, 49:322-327
	Threonine(T) 174 □ methionine (M)	Elevated levels of Plasma angiotensinogen, hypertension, and left ventricular hypertrophy	exhibit better responsesto ACE inhibitor treatment or AT1R blockade	Fajar et.al, Gene Reports 2019 16:100421, Pilbrow et al,, *Hypertension,* 2007, 49:322-327
ACE	An insertion (I)/deletion (D)	Heart failure incidenceand severity	90% receiving ACE inhibitors carriers of theD allele improved LVEFcompared to wild-type patients after a mean follow-up of 39 months	Oni-Orisan and Lanfear, *Cardiol Rev*. 2014 ; 22(5): 193–198

Gen	Polymorphism	Functional consequence	Therapeutic implication	Ref
			(conflicting data)	
Angiotensin II Type 1 Receptors	*A1166C* adenine 1,166 □cytosine.	Increased sensitivity to angiotensin II greater response to angiotensin II, aortic stiffness myocardial infarction, hypertension, and LVH in hypertensive patients	C carriers experienced the greatest decrease in NT-proBNP, a biomarker LV remodeling, particularly benefit from **high doses** of candesartan	*S de Denus et al.The Annals of Pharmacotherapy* n *2008,* 42:925-32
Angiotensin II Type 2 Receptors	*A3123C* adenine 3123 □cytosine.	Associated with non-concentric cardiac remodeling as an adaptive response to EHT		Mocan *et al,*Biomedical reports 15: 80, 2021

There are relationships between the Renin-angiotensin-aldosterone systemic (RAAS) pathway, the adrenergic receptor, the site of action of drug therapies, and functional polymorphisms. As shown in the figure below (Fig.1), myocardial injury and diminished cardiac function activate the sympathetic system by releasing norepinephrine and causing the releaseof renin to initiate the RAAS pathway. Functional genomic polymorphisms can affect any stage of the pathway and appear to influence therapy targeted at the RAAS pathway. Genomicvariants at any stage of the pathway have been extensively explored in subjects with hypertension and heart failure (Mann et al., 2011).



Figure 2. The Relationships between the Renin-angiotensin-aldosterone systemic (RAAS) pathway, the adrenergic receptor, the site of action of drug therapies, and functional polymorphisms[2]

Integration of Our Research

Our investigation into the pharmacogenomic analysis of polymorphisms in beta2-adrenergic receptors in hypertensive patients treated with angiotensin II receptor blocker (ARB) in combination with bisoprolol demonstrated a regression of left ventricular hypertrophy. Beta-AR signaling in the heart will regulate heart rate (chronotropic), contractility (inotropic), and relaxation (lusitropic). Recent evidence suggests that the important role of beta2-AR signaling and long-term cardiac remodeling includes the regulation of hypertrophy and apoptosis. It is thought that Glu27 of beta2-AR regulates the exaggerated hypertrophic response to catecholamines and associated with the development of LV hypertrophy in hypertensive patients.

The conceptual framework of our study makes reference to a number of publications about the beta-2 adrenergic receptor (AR) polymorphisme, which is closely linked to left ventricular hypertrophy (Fig.2). In the physiological condition of beta2-AR of the heart is relatively less, but in hypertension, this receptor will be upregulated while beta-1 AR is downregulated, and we interest to investigate ARB response to LVH regression with polymorphism beta-AR in hypertensive patients. The concept tried to investigate and prove the Angiotensin II receptor blockers properties by blocking neurohormonal system and lowering blood pressure in LV hypertrophy patients with polymorphism Gln27, ARB may suppress the catecholamine as a hypertrophic response through inhibition of AT1 receptors on sympathetic nerves in the heart and regress LV mass.



Figure 3. The Conceptual Framework of Left Ventricular Hypertrophy Regression in HypertensivePatients with Gln27 β2-Adrenergic Receptor Received Angiotensin II Receptor Blocker Combination with Bisoprolol

Design of this study using pre-posttest prospective cohort study and we screened 39 hypertensive male patients who met inclusion criteria (newly diagnosed hypertension or no taking antihypertensive medication more than 2 weeks, age 30-75 years, Asian race). All patients underwent 24-hours Ambulatory Blood Pressure Monitoring (ABMP), echocardiography examination to assess left ventricular hypertrophy before and after 6 months of ARB-based antihypertensive. We followed up every month and optimized a regimens based on office blood pressure. During follow up we examined Genotype using Restriction Fragment Length Polymorphism (RFLP) analysis. At the end of study we identified Left ventricular hypertrophy patients into two group of genetic beta2-AR variants, Gln27 homozygote and Gln27Glu



Figure 4. Flowchart of the study. ARB,Angiotensin Receptor Blocker; ABMP, Ambulatory Blood Pressure Monitoring; PCR-RFLF, Polymerase Chain Reaction- Restriction Fragment Length Polymorphism; LVH, Left Ventricular Hypertrophy; Gln27Gln, Glutamine 27 homozygote; Glu27Glu, Glutamine 27 Glutamic acid

The result of this study, based on the basic characteristics of research subjects (table 3), included the duration of hypertension, basal mass index (BMI), systolic blood pressure (BP), diastolic BP, left ventricular septal thickness (LVSWT), left ventricular posterior wall (LVPW), leftventricular mass index(LVMi) , left ventricular mass (LVmass) and relative wall thickness (RWT) showed no significant difference between the observed characteristics. Frequency genomic variant of beta2-AR, the Gln27Gln was found 84.6% in hypertensive patients and 81.25% in LVH.

Table 3. Basic Characteristics of Research Subjects

Parameter Subject	Gln/Gln (n=33)	Gln27Glu(n=6)	**P value**
Age (y)	55.97 ± 10.89	58.83 ± 4.79	0.585
Duration of Hypertension(y)	6.19 ± 5.27	7.60 ± 10.71	0.876
BMI (kg/m^2)	25.67 ± 4.22	26.59 ± 4.92	0.688
SBP 24 hours (mmHg)	141.79 ± 16.64	134.88 ± 10.20	0.335
DBP 24 hours (mmHg)	88.66 ± 12.74	89.37 ± 8.43	0.898
IV ST (mm)	1.19 ± 0.33	1.29 ± 0.35	0.447
LV PWT (mm)	1.22 ± 0.27	1.21 ± 0.27	0.953
LVMi (g/m^2)	118.91 ± 50.51	118.83 ± 41.51	0.846
LVMass (gr)	208.30 ± 88.13	211.33 ± 74.91	0.835
RWT (%)	0.56 ± 0.17	0.55 ± 0.12	0.846

BMI. Body Mass Index; SBP, systolic Blood Pressure; DBP, Diastolic Blood Pressure; LVH, left ventricular hypertrophy; LVMI left ventricle mass index, IVST inter ventricular septal thickness, LV PWT, Left Ventricular posterior wall thickness, LVMi, Left Ventricular Mass index; LVMass, Left Ventricular Mass; RWT, Regional Wall Thickness.

Following a 6-month course of ARB treatment, patients carrying the Gln27Gln genotype showed a 24-hour reduction in systolic blood pressure of 11 mmHg (p = 0.028) and diastolic blood pressure of 8 mmHg (0.015). Additionally, the mean reduction in LVMi was around 59 gr/m2 (p = 0.03) following ARB-based treatment. These changes indicate an improvement from concentric hypertrophy towards concentric remodeling, while Gln2Glu showed significant reductions in regional wall thickness (RWT), indicate a deterioration towards eccentric hypertrophy and there were no improvement from blood pressure neither systolic nor diastolic.

Table 4. Parameters of Regression Variables Before and After ARB-Based Therapies in LVH Groups with Genotype of the ß2-Adrenergic Receptor

Parameter of Regression Variable	**Gln/Gln (n=13) Before Treatment**	**Gln/Gln (n=13) After 6m Follow-up**	**Gln27Glu (n=3) Before Treatment**	**Gln27Glu (n=3) After 6m Follow-up**
SBP 24h (mmHg)	150.46 ± 16.25	139.52 ± 14.08*	140.90 ± 6.39	145.67 ± 19.39
DBP 24h (mmHg)	92.23 ± 14.15	84.26 ± 9.02*	92.73 ± 10.89	93.83 ± 10.85
LVMi (g/m²)	169.00 ± 42.98	110.61 ± 57.03*	153.33 ± 15.63	158.67 ± 99.12
LVMass	293.08 ± 76.40	187.46 ± 70.48*	274.00 ± 43.48	166.67 ± 43.59
RWT	0.55 ± 0.12	0.51 ± 0.20	0.63 ± 0.08	0.50 ± 0.12*



Figure 5. Influence of ARB-Based Treatmentsin LVH Groups with ß2-Adrenergic Receptor Genotype Gln/Gln



Figure 6. Influence of ARB-Based Treatmentsin LVH Groups with ß2-Adrenergic Receptor Genotype Gln/Glu

Adding beta-blocker to ARBs in the Gln27Gln after 6 months revealed significant decreased in LVMI from 137.11 to 72.56 (p=0.011) and RWT revealed decreased but notsignificant, these alteration indicate an improvement from concentric hypertrophy towards normal geometry.



Figure 7. Influence of beta-blocker (bisoprolol) addition on ARB-Based Treatmentsin LVH Groups with ß2-Adrenergic Receptor Genotype Gln/Gln

Table 5. Regression variable parameters before and after beta-blocker (bisoprolol) addition inARB-based therapies in LVH groups with ß2-Adrenergic receptor genotypes

Parameter	Gln27Gln Before Therapy	Gln27Gln After 6mo Therapy	Gln27Gln P-Value	Gln27Glu Before Therapy	Gln27Glu After 6mo Therapy	Gln27Glu P-Value
SBP	149.96 ± 16.90	140.23 ± 16.90	0.26	137.80 ± 14.57	144.90 ± 32.24	655
DBP	92.60 ± 12.80	84.28 ± 9.80	173	94.95 ± 14.35	94.15 ± 30.19	655
LVMI	137.11 ± 37.58	72.56 ± 28.59	0.011*	124.00 ± 21.21	83.00 ± 4.24	0.18
LVMass	243.22 ± 72.69	141.22 ± 36.87	0.011*	212.50 ± 45.96	142.50 ± 0.71	0.18
RWT	0.54 ± 0.17	0.44 ± 0.19	154	0.54 ± 0.05	0.40 ± 0.06	0.18

Discussion

Genetic polymorphisms impact drug metabolism through altering how the drug is metabolized, producing hazardous or sub-therapeutic levels, and influencing the drug's ability to attach to target proteins as carriers or receptors, which can result in a successfulpharmacological response or therapy failure. There is genetic variability in response to heart failure treatment and genetic information may complement conventional clinical information in tailoring therapy to an individual patient. Treatment with ARB-based antihypertensive revealed asignificant decreased of blood pressure and reverse cardiac remodeling by regression of LVH in Gln27Gln genotype. The combination of beta-blockers and ARBs may significantly improve LVHregression compared with ARBs alone in Gln27Gln genotype. This data shows genetic variability provides evidence that can influence pharmacogenomics in drug responses, and provides insights into the potential role of using genetic information to improve drug therapy outcomes. The ß2-Adrenergic Gln/Gln Receptor genotype is the specific genetic variant that appears to be most relevant to pharmacogenomics in drug response for LVH, and the potential challenges to developing this research further as well as the limitations in applying a more personalized approach based on genetic data require significant costs and time in order to obtain more precise treatment results.

The ß2-Adrenergic Gln/Gln Receptor genotype has emerged as a potentially significant genetic variant in pharmacogenomics research for LVH and drug response. Studies suggest variations in this gene influence response to beta-blockermedications and ARBs commonly used for managing LVH, potentially impacting treatment efficacy and side effects. However, developing and implementing personalized medicine based on ß2-adrenergic receptor genotype and other genetic factors in LVH faces several challenges:

1. Limited evidence: While preliminary research shows promise, further studies are needed to solidify the clinical utility of ß2-adrenergic receptor genotyping in guiding LVH treatment. Larger, well-designed clinical trials are necessary to validate these findings and establish concrete pharmacogenomic recommendations for LVH patients.
2. Multifactorial complexity: LVH and its response to treatment are influenced by diverse factors beyond genetics, including underlying causes, comorbidities, lifestyle habits, and other medications. While genetic information can offer valuable insights, it requires comprehensive integration with other clinical data for accurate interpretation and personalized treatment planning.
3. Cost and accessibility: Implementing genetic testing and pharmacogenomic analysis into routine clinical practice requires significant infrastructure and financial resources. Equitable access to these technologies remains a challenge, particularly in low-resource settings.
4. Ethical considerations: Privacy concerns, potential for genetic discrimination, and informed consent processes need careful consideration when incorporating genetic information into healthcare. Clear ethical guidelines and patient education are crucial for responsible implementation of pharmacogenomics.
5. Continuous evolution: The field of pharmacogenomics is rapidly evolving, with new genetic variants and drug interactions being discovered regularly. Healthcare professionals need continuous education and updated guidelines to stay abreast of the latest advancementsand effectively apply them in clinical practice.

CONCLUSION

Despite these challenges, the potential benefits of personalized medicine based ongenetic data for LVH patients are considerable. By tailoring treatment strategies to individual genetic profiles, we can potentially improve medication efficacy and reduce adverse effects, optimize dosing regimens and personalize treatment plans, identify patients who may not benefit from specific medications, avoiding unnecessary therapy and risks, develop novel targeted therapies based on identified genetic pathways. While overcoming the current challenges will require ongoing research, collaboration, and ethical considerations, the future of personalized medicine for LVH and other cardiovascular diseases holds immense promise for improving patient care and outcomes.

REFERENCES

Ahmed, S., Zhou, Z., Zhou, J., & Chen, S. Q. (2016). Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. *Genomics Proteomics Bioinformatics*, *14*, 298-313.

Boulet, J., & Mehra, M. R. (2021). Review article: Left ventricular reverse remodeling in heart failure: remission to recovery. *Structural Heart*, *5*(5), 466-481.

Cardoso, J. N., Ribeiro, J. M., Santos Junior, J. B. F., de Oliveira, T. M. S., & Sobrinho, C. R. V. (2015). Reverse cardiac remodeling in heart failure: a review of therapeutic strategies. *Arq Bras Cardiol*, *104*(6), 502-506.

Cascorbi, I., & al., et. (2004). Review: Pharmacogenomics of heart failure - focus on drug disposition and action. *Cardiovascular Research*, *64*, 32-39.

Cohn, J. N., Ferrari, R., & Sharpe, N. (2000). Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol*, *35*(3), 569-582.

De Denus, S., Letarte, N., Hurlimann, T., & al., et. (2008). Polymorphisms of CYP3A5 and CYP2C19 are associated with increased variability in plasma concentrations of tacrolimus in heart transplant recipients. *Ann Pharmacother*, *42*(7), 925–932.

Dorn, G. W. 2nd, & Liggett, S. B. (2007). Cardiac adrenergic pathway pharmacogenomics. *CTS*, *1*(3), 343–350.

Fajar, J. K., Azwar, M. K., Lukita, C. D., & al., et. (2019). Pharmacogenomic aspects of clopidogrel: an update. *Gene Reports*, *16*, 100421.

Femminella, G. D., Ferrara, N., & Rengo, G. (2014). Pharmacogenomics and personalized medicine. *Pharmacogenomics Pers Med*, *7*, 349–359.

Iaccarino, G., & al., et. (2006). β2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. *Clinical Pharmacology & Therapeutics*, *80*(6), 633–645.

Johnson, J. A., & Cavallari, L. H. (2013). Pharmacogenetics and cardiovascular disease--implications for personalized medicine. *Pharmacol Rev*, *65*(3), 987–1009. https://doi.org/10.1124/pr.113.007427

Mann, D. L., & McNamara, D. M. (2008). Pharmacogenomics and the Failing Heart: Are We Waiting for Godot? *JACC*, *52*(8).

Mann, D. L., Zipes, D. P., Libby, P., Bonow, R. O., & Braunwald, E. (2011). *Heart Failure: A Companion to Braunwald's Heart Disease* (D. L. Mann & 2nd, Eds.).

Mocan, H., Iacob, D., Parepa, I. R., & al., et. (2021). Pharmacogenomics of antihypertensive drugs: a perspective from next-generation sequencing. *Biomed Rep*, *15*(2), 80.

Oni-Orisan, A., & Lanfear, D. E. (2014). Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? *Cardiol Rev*, *22*(5), 199–207.

Petersen, M., Khan, J., Viney, N. J., & al., et. (2011). Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants. *Br J Clin Pharmacol*, *71*(4), 351–364.